🔗 Share this article

As the United States proceeds with historic changes to its immunization recommendations, a particular individual has emerged in a surprising turn: Høeg, a Danish American physician and public health researcher who initially gained attention by expressing skepticism about Covid shots during the global health crisis and has concentrated on possible deaths following COVID-19 immunization in her recent tenure at the FDA.

Scheduled Overhauls to Childhood Vaccine Program

Health officials had intended to reveal sweeping revisions to the pediatric immunization program recently, aligning the US with Denmark’s national calendar, sources say – a substantial departure that would place the US at odds with much of the global community with no evidence for public health gain. This reveal has been pushed back until the new year.

Rather than Vinay Prasad, Tracy Beth Høeg is listed to address the audience at the gathering. She was just designated acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth appointee to run the office this year.

A Shift at the FDA

This interim role may indicate a strengthened alliance between the pharmaceutical and biologics divisions as Dr. Høeg and Dr. Prasad solidify control at the agency – and it points to a renewed priority upon reevaluating long-standing vaccines at the FDA.

Høeg has often pushed for ending some pediatric vaccine recommendations in the US in order to be more like the Danish model, a country with comprehensive healthcare and a population roughly the population of the state of Wisconsin.

To date public appearances, she has persisted in emphasizing on vaccination policy – usually the domain of Prasad, head of the FDA’s CBER – instead of pharmaceutical oversight.

Doubts Over Qualifications

Dr. Høeg has little discernible experience in pharmaceutical research, oversight or management, which has been customary for previous directors of the biologics center. She has been employed at the FDA as a top consultant to the commissioner and the vaccine center since spring.

“She appears not to have the requisite experience” for running the drug-regulation department, said Dr. Jonathan Howard. “She has not conducted a clinical trial. She has no expertise in managing a sizeable institution. She has no expertise in drug approvals.”

Previous commissioners of CBER would “be deeply familiar with legal statutes and the underlying principles of medication creation”, said a former acting FDA commissioner. “Clearly, she has not acquired the type of experience that former directors who led the center have had.”

The drug center has an immense workload at the FDA, Woodcock emphasized.

“Everybody just focuses on the novel medication approvals, but the generic drug division clears thousands of off-brand pharmaceuticals. There’s a biosimilars program, OTC medication office and more, and every single one need to be supervised,” Dr. Woodcock noted. “The thing you don’t keep your eye on, that is precisely what that I always told people is going to cause problems.”

Additionally, a major management aspect to the job, which supervises in excess of 5,000 personnel. “It is a enormous administrative position, if you do it right,” she added.

Response and Disputed Programs

In response to concerns about Høeg’s credentials and whether this appointment indicates more teamwork among agency officials on immunizations, a press secretary responded that the “questions are based on flawed premises”.

“Her experience aligns with the responsibilities of her job,” the official explained, noting the months Høeg spent counseling the agency head on “medication safety and approval science, including computerized risk analysis and shot safety tracking”.

As acting director, Dr. Høeg takes over the agency head's new expedited review system, a contentious one-day medication authorization process that reportedly concerned her predecessors. “How are these drugs being selected for this voucher program? Who is making the decisions?” Howard questioned. “There’s a lot of lack of transparency happening at the FDA right now.”

In general, he remarked, “the FDA looks to be trending towards less stringent oversight of all drugs, with the exception of vaccines.”

Public Past Work on Immunizations

Regarding vaccines, Dr. Høeg has a more documented, if problematic, past, some experts observe. She authored a study using unconfirmed volunteer-provided data to estimate the incidence of myocarditis after Covid immunization. She consulted for the Florida chief medical officer Dr. Joseph Ladapo, who allegedly have modified findings to suggest COVID-19 vaccines are more dangerous than they are.

Part of her “wish list” for the new federal leadership encompassed altering guidelines for new vaccines and halting “unnecessary” vaccines, she stated after the election on a audio program. At the agency, Dr. Høeg has reportedly suggested barring young men from obtaining COVID-19 vaccines.

“She’s an thorough dogmatist who commences with her conclusions and tailors the evidence to accommodate the evidence in a highly deceptive, untruthful way,” Dr. Howard argued.

Consolidating Power and a “Campaign of Retribution”

Dr. Høeg became part of fellow contrarians, {like|